Thermo Fisher Scientific Inotuzumab Humanized Recombinant Human Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Human / IgG4, kappa

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Human CD22

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

2.7 mg/mL

Purification

Protein A

Storage buffer

PBS, pH 7.4

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2910997

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Inotuzumab ozogamicin is an antibody-pharmaceutical conjugate using linker and cytotoxic pharmaceutical technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukemia. Inotuzumab ozogamicin consists of a recombinant humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relapsing conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.